Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo and Amplimmune announce new collaboration

Daiichi Sankyo and Amplimmune announce new collaboration

11th January 2013

Daiichi Sankyo and Amplimmune have signed an agreement that will see them collaborating on the development of a new therapeutic protein called AMP-110.

The companies will carry out joint research into the potential immune modulation therapy for autoimmune diseases, which is set to commence phase I clinical testing in the first half of 2013.

Amplimmune will receive an undisclosed option fee and more than $50 million (31.03 million pounds) to cover past and planned research and development costs for the compound up to phase II trials.

Daiichi Sankyo will have an exclusive option to acquire the AMP-110 programme should it prove to be successful.

Dr Glenn Gormley, global head of research and development and senior executive officer of Daiichi Sankyo, said: "Immune modulation therapy is one of the exciting areas of autoimmune disease research that has the potential to meet an unmet medical need."

The company is headquartered in Tokyo and was founded in 2005, with its worldwide workforce now coming to approximately 32,000.ADNFCR-8000103-ID-801520603-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.